Your browser doesn't support javascript.
loading
Identification of Small Molecules Disrupting the Ubiquitin Proteasome System in Malaria.
Mata-Cantero, Lydia; Chaparro, María Jesús; Colmenarejo, Gonzalo; Cid, Concepción; Cortes Cabrera, Alvaro; Rodriguez, Manuel S; Martín, Julio; Gamo, Francisco Javier; Gomez-Lorenzo, Maria G.
Afiliación
  • Mata-Cantero L; Tres Cantos Medicines Development Campus, Diseases of the Developing World . GlaxoSmithKline , Severo Ochoa 2 , Tres Cantos , 28760 Madrid , Spain.
  • Chaparro MJ; Tres Cantos Medicines Development Campus, Diseases of the Developing World . GlaxoSmithKline , Severo Ochoa 2 , Tres Cantos , 28760 Madrid , Spain.
  • Colmenarejo G; Tres Cantos Medicines Development Campus, Diseases of the Developing World . GlaxoSmithKline , Severo Ochoa 2 , Tres Cantos , 28760 Madrid , Spain.
  • Cid C; IMDEA Food , Biostatistics and Bioinformatics Unit , Ctra Cantoblanco 8 , 28049 Madrid , Spain.
  • Cortes Cabrera A; Tres Cantos Medicines Development Campus, Diseases of the Developing World . GlaxoSmithKline , Severo Ochoa 2 , Tres Cantos , 28760 Madrid , Spain.
  • Rodriguez MS; Tres Cantos Medicines Development Campus, Diseases of the Developing World . GlaxoSmithKline , Severo Ochoa 2 , Tres Cantos , 28760 Madrid , Spain.
  • Martín J; Université de Toulouse , ITAV CNRS and IPBS CNRS , 1 place Pierre Potier, Oncopole entrée B , 31106 Toulouse , France.
  • Gamo FJ; Tres Cantos Medicines Development Campus, Diseases of the Developing World . GlaxoSmithKline , Severo Ochoa 2 , Tres Cantos , 28760 Madrid , Spain.
  • Gomez-Lorenzo MG; Tres Cantos Medicines Development Campus, Diseases of the Developing World . GlaxoSmithKline , Severo Ochoa 2 , Tres Cantos , 28760 Madrid , Spain.
ACS Infect Dis ; 5(12): 2105-2117, 2019 12 13.
Article en En | MEDLINE | ID: mdl-31644867
ABSTRACT
The ubiquitin proteasome system (UPS) is one of the main proteolytic pathways in eukaryotic cells, playing an essential role in key cellular processes such as cell cycling and signal transduction. Changes in some of the components of this pathway have been implicated in various conditions, including cancer and infectious diseases such as malaria. The success of therapies based on proteasome inhibitors has been shown in human clinical trials. In addition to its proven tractability, the essentiality of the Plasmodium falciparum UPS underlines its potential as a source of targets to identify new antimalarial treatments. Two assays, previously developed to quantify the parasite protein ubiquitylation levels in a high throughput format, have been used to identify compounds that inhibit parasite growth by targeting P. falciparum UPS. Among the positive hits, specific inhibitors of the P. falciparum proteasome have been identified and characterized. Hits identified using this approach may be used as starting points for development of new antimalarial drugs. They may also be used as tools to further understand proteasome function and to identify new targets in P. falciparum UPS.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Asunto principal: Plasmodium falciparum / Proteínas Protozoarias / Antimaláricos Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: ACS Infect Dis Año: 2019 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Asunto principal: Plasmodium falciparum / Proteínas Protozoarias / Antimaláricos Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: ACS Infect Dis Año: 2019 Tipo del documento: Article País de afiliación: España